Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis

Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis

Abstract Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that t...

Full description

Bibliographic Details
Main Authors: Kento Tomizawa, Ken Ando, Hirofumi Shimada, Takuya Kaminuma, Kazutoshi Murata, Takahiro Oike, Tatsuya Ohno
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Clinical Case Reports
Subjects:
bevacizumab
cervical cancer
dose‐volume analysis
radiation
rectovaginal fistula
Online Access:https://doi.org/10.1002/ccr3.3955
id doaj-bebb6a3457d24303bf366bf123c81a2c
record_format Article
spelling doaj-bebb6a3457d24303bf366bf123c81a2c2021-05-15T18:35:45ZengWileyClinical Case Reports2050-09042021-04-01942099210410.1002/ccr3.3955Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysisKento Tomizawa0Ken Ando1Hirofumi Shimada2Takuya Kaminuma3Kazutoshi Murata4Takahiro Oike5Tatsuya Ohno6Department of Radiation Oncology Gunma University Graduate School of Medicine Gunma JapanDepartment of Radiation Oncology Gunma University Graduate School of Medicine Gunma JapanGunma University Heavy Ion Medical Center Gunma JapanDepartment of Radiation Oncology Gunma University Graduate School of Medicine Gunma JapanDepartment of Radiation Oncology Gunma University Graduate School of Medicine Gunma JapanDepartment of Radiation Oncology Gunma University Graduate School of Medicine Gunma JapanDepartment of Radiation Oncology Gunma University Graduate School of Medicine Gunma JapanAbstract Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side effect may be unpredictable by the conventional dose‐volume parameters for the rectum.https://doi.org/10.1002/ccr3.3955bevacizumabcervical cancerdose‐volume analysisradiationrectovaginal fistula
collection DOAJ
language English
format Article
sources DOAJ
author Kento Tomizawa
Ken Ando
Hirofumi Shimada
Takuya Kaminuma
Kazutoshi Murata
Takahiro Oike
Tatsuya Ohno
spellingShingle Kento Tomizawa
Ken Ando
Hirofumi Shimada
Takuya Kaminuma
Kazutoshi Murata
Takahiro Oike
Tatsuya Ohno
Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis
Clinical Case Reports
bevacizumab
cervical cancer
dose‐volume analysis
radiation
rectovaginal fistula
author_facet Kento Tomizawa
Ken Ando
Hirofumi Shimada
Takuya Kaminuma
Kazutoshi Murata
Takahiro Oike
Tatsuya Ohno
author_sort Kento Tomizawa
title Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis
title_short Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis
title_full Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis
title_fullStr Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis
title_full_unstemmed Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis
title_sort rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: a dose‐volume analysis
publisher Wiley
series Clinical Case Reports
issn 2050-0904
publishDate 2021-04-01
description Abstract Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side effect may be unpredictable by the conventional dose‐volume parameters for the rectum.
topic bevacizumab
cervical cancer
dose‐volume analysis
radiation
rectovaginal fistula
url https://doi.org/10.1002/ccr3.3955
work_keys_str_mv AT kentotomizawa rectovaginalfistulainacervicalcancerpatienttreatedwithsequentialradiotherapyandbevacizumabadosevolumeanalysis
AT kenando rectovaginalfistulainacervicalcancerpatienttreatedwithsequentialradiotherapyandbevacizumabadosevolumeanalysis
AT hirofumishimada rectovaginalfistulainacervicalcancerpatienttreatedwithsequentialradiotherapyandbevacizumabadosevolumeanalysis
AT takuyakaminuma rectovaginalfistulainacervicalcancerpatienttreatedwithsequentialradiotherapyandbevacizumabadosevolumeanalysis
AT kazutoshimurata rectovaginalfistulainacervicalcancerpatienttreatedwithsequentialradiotherapyandbevacizumabadosevolumeanalysis
AT takahirooike rectovaginalfistulainacervicalcancerpatienttreatedwithsequentialradiotherapyandbevacizumabadosevolumeanalysis
AT tatsuyaohno rectovaginalfistulainacervicalcancerpatienttreatedwithsequentialradiotherapyandbevacizumabadosevolumeanalysis
_version_ 1721440502296870912

Similar Items